TRACON Pharmaceuticals welcomes Saundra Pelletier to its Board of Directors

– USA, CA –  TRACON Pharmaceuticals (NASDAQ: TCON), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the appointment of Saundra Pelletier, CEO, President and Executive Director of Evofem Biosciences, Inc., to its Board of Directors.

“We are very pleased to welcome Saundra to the TRACON Board,” said Dr. Charles Theuer, President and CEO. “Her strong track record of successful strategic, operational and financial management, combined with her vast commercial experience will be invaluable to TRACON as we execute on our plan to complete clinical development and commercialize envafolimab in the United States by 2023.”

About Saundra Pelletier

Ms. Pelletier brings more than two decades of broad executive leadership experience to TRACON, including an outstanding track record leading multiple successful product launches, expanding commercial capabilities in ex-U.S. markets and advocating for women’s health. She is currently Chief Executive Officer, President and Executive Director of Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company focused on women’s sexual and reproductive health, where she is leading the Company’s effort to bring Phexxi, a new, non-hormonal contraceptive candidate, to women. Among her many honors, Ms. Pelletier was named San Diego Business Journal’s 2019 Businesswoman of the Year.

“TRACON has a first-class management team, an efficient platform to conduct global clinical trials and a promising drug candidate with near-term commercial potential in envafolimab,” said Ms. Pelletier. “As a cancer survivor and woman’s health advocate, I am thrilled to support TRACON’s mission and help advance its broad oncology pipeline, which has the potential to address significant unmet needs across multiple tumor types.”

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital-efficient product development platform. The Company’s clinical-stage pipeline includes Envafolimab, a subcutaneous PD-L1 single-domain antibody being developed for the treatment of sarcoma; TRC102, a small molecule drug being developed for the treatment of lung cancer; TRC253, a small molecule drug being developed for the treatment of prostate cancer; and TJ004309, a CD73 antibody being developed for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships, TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.

For more information: https://www.traconpharma.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>